ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • Highlighting the Relationship between Hepatitis B and Liver Cancer

    … of Hepatology, 66(2), 355-362. https://doi.org/10.1016/j.jhep.2016.09.013 Cudjoe, J., Gallo, J.J., Sharps, P., Budhathoki, C., Roter, D., & Han, H-R. (2021). The role of sources and types of health information in shaping health literacy in cervical cancer screening among African immigrant women: A mixed-methods study. Health Literacy Research and Practice, 5(2), e96-e108. doi: 10.3928/24748307-20210322-01 Department of Health and Human Services. (2014). Action plan for the prevention, care, & treatment of viral hepatitis. Department of Health and Human Services. Hong, Y.A., Juon, H.S., & Chou, W.Y.S. (2021). Social media apps used by immigrants in the United States: Challenges and opportunities for public health research and practice. mHealth, 7, 52. doi: 10.21037/mhealth-20-133 Hong, Y.A., Yee, S., Bagchi, P., Juon, H.S., Kim, S.C., & Le, D. (2022). Social media-based intervention to promote HBV screening and liver cancer prevention among Korean Americans: Results of a pilot study. Digital Health, 8, 20552076221076257. https://doi.org/10.1177/20552076221076257  Joo, J.Y. (2014). Effectiveness of culturally tailored diabetes interventions for Asian immigrants to the United States: A systematic review. The Diabetes Educator, 40(5), 605-615. DOI: 10.1177/0145721714534994 Parvanta, C., & Bass, S. (2018). Health communication: Strategies and skills for a new era: strategies and skills for a new era. Jones & Bartlett Learning, LLC. Porteny, T., Alegria, M., del Cueto, P., Fuentes, L., Lapatin Markle, S., NeMoyer, A., & Perez, G.K. (2020). Barriers and strategies for implementing community-based interventions with minority elders: Positive minds-strong bodies. Implementation Science Communications, 1, 41. doi: 10.1186/s43058-020-00034-4 Taylor, V.M., Bastani, R., Burke, N., Talbot, J., Sos, C., Liu, Q., Jackson, J.C., & Yasui, Y. (2013). Evaluation of a hepatitis B lay health worker intervention for Cambodian Americans. Journal of

    http://www.hepb.org/blog/highlighting-relationship-hepatitis-b-liver-cancer/
  • Team Helpatitis: Students and Teachers Come Together to Raise Awareness of Hepatitis B in India! 

    … administration, Team Helpatitis has expanded their reach beyond the classroom and amplified the voices of public health workers, advocates, and people living with hepatitis B! Check out Team Helpatitis’ social media channels to stay updated!  Team Helpatitis' Instagram:  https://www.instagram.com/helpatitis_aisv1_yppteam/    References:  chrome extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.who.int/docs/default-source/searo/india/health-topic-pdf/factsheet-b-hepatitisday2016.pdf?sfvrsn=da61ef0_2#:~:text=In%20India%2C%20the%20prevalence%20of,D%2C%20followed%20by%20Aand%20C.  Premkumar, M., & Kumar Chawla, Y. (2021). Chronic Hepatitis B: Challenges and Successes in India. Clinical liver disease, 18(3), 111–116. https://doi.org/10.1002/cld.1125   

    http://www.hepb.org/blog/8126-2/
  • 2017 A Year in Review

    … your friends to follow us and like the page!   The Hepatitis Delta Connect program had a breakout year since its 2016 launch with over 11,000 website views from over 4,000 patients and providers in 92 countries! Hepatitis Delta Connect reaches 4,650 people on social media through Facebook, Twitter, and Instagram. Not bad for the first-of-its kind outreach and awareness program!  With Hep B United, our national coalition, we distributed 6 mini-grants this year and held 12 hep B virtual training seminars reaching 2,000 live attendees and nearly 6,000 online viewers! We also had a record number of attendees at our annual Hep B United Summit during World Hepatitis Day in Washington D.C.! Together, our partners screened 4,649 people, educated 11,884 people, gave out 13,112 hepatitis B handouts, and were featured in 2 newspapers, 1 TV appearance (496,189 views), and 1 social media video. Hep B United has a social media reach that includes over 1,500 people across Facebook, Twitter, and Instagram.   Our newest program, the #justB storytelling campaign, has been very successful so far. We now have 15 storytellers, ranging in age from 21 to 75, representing 10 U.S. states, and sharing a diversity of stories around HBV and liver cancer, transplantation, treatment, stigma and disclosure. The #justB digital stories were released on May 1, 2017, in recognition of Hepatitis Awareness Month, on HBF’s YouTube Channel and at www.hepb.org/justb. Since the launch, there have been over 60,000 views of the 18 multi-lingual videos! We want to thank our partners for helping promote these videos, including CDC Division of Viral Hepatitis Shot By Shot in California. And We are very proud that a few of the videos were selected for screening at the American Public Health Association Annual Film Festival and the Philadelphia Asian American Film Festival.  Our storytellers have been very busy this year! They have conducted local hepatitis B education in their home towns, and have given

    http://www.hepb.org/blog/6208-2/
  • Be Brave: Join a Hepatitis B Clinical Trial and Help Find a Cure

    … and any other lab results can be performed locally and sent to the researchers. Step 4: Do your research before you participate. Ask questions and make sure you understand how the trial will affect your health. If there's a chance you'll get the placebo pill, ask what will happen and if you get access to the drug later on. Make sure you get the information in your primary language and that trial doctors are culturally-sensitive. Trust and knowledge is essential. Below are some resources to help you. If you need more information, contact the foundation at 215-489-4900 (U.S.) or email info@hepb.org. Where to find a clinical trial Hepatitis B Foundation’s directory  of hepatitis B-related clinical trials: This resource lists hepatitis B-related clinical trials registered with the U.S. National Institutes of Health. These include hepatitis B-related treatment and liver cancer trials for adults and children in the U.S. and around the world. They also include coinfections, hepatitis D and trials investigating ways to prevent mother-to-children transmission of hepatitis B during childbirth. You can also email the foundation for more information at info@hepb.org. The U.S. National Institutes of Health directory of clinical trials. This is a searchable directory of all NIH-approved clinical trials. You can search by condition and location. Center for Information & Study on Clinical Research Participation: This offers a clinical trial database you can search, and the organization will also help you find clinical trials and email or mail you the information.  Call 877-MED HERO. Allow one to two weeks for response. To watch a webinar about how to participate in a clinical trial, click here.

    http://www.hepb.org/blog/brave-join-hepatitis-b-clinical-trial-help-find-cure-httpwww-hepb-orgblogp5479/
  • In America, It Takes a Coalition to Combat Hepatitis B

    Hep B United Summit members meet with California lawmakers in Washington DC. By Christine Kukka In late July, during World Hepatitis Day 2016, the fourth annual Hep B United Summit convened in Washington D.C. and dozens of advocates met with federal officials and brainstormed strategies to increase screening, immunization and linking people to care to eliminate hepatitis B across the country. The Hepatitis B Foundation and the Association of Asian Pacific Community Health Organization (AAPCHO) established Hep B United in 2011 to address the silent epidemic of hepatitis B. The liver disease infects 2 million people in the U.S., and 67 percent don’t know they’re infected. Asian-American and Pacific Islanders (AAPI) and African immigrant Members of the Hep B United 2016 Summit in Washington DC. communities are among those hardest hit. Crafting a culturally- and liguistically-adept approach on small or non-existent budgets to educate and screen these diverse populations remains a challenge for Hep B United’s  more than 30 community coalitions in 15 states and Washington D.C. On the upside, the coalition's organizations have educated 4 million Americans and screened about 40,000. However, large swaths of the country lack outreach efforts to prevent the spread of hepatitis B. For a map and list of Hep B United Summit member organizations, click here. The coalition’s ongoing hepatitis B prevention efforts mirror HIV and hepatitis C campaigns that have sought to increase education, screening, and linkage to care. But in many respects, Hep B advocates face more challenges: Because there is a safe and effective vaccine that prevents hepatitis B, many state and federal health officials assume the infection will go away on its own and government resources for screening and prevention have been minimal. Many immigrant populations affected by hepatitis B have unique languages and cultures, which requires careful, individual approaches to each community. Federal

    http://www.hepb.org/blog/america-takes-coalition-eradicate-hepatitis-b/
  • French

    Bienvenue sur le site internet français de Hepatitis B Foundation ! L'hépatite B est une maladie « silencieuse ». La plupart des personnes atteintes ignorent qu’elles le sont. Ce site internet contient des informations sur la prévention, le diagnostic et le traitement de l'hépatite B. N’hésitez pas à communiquer ces informations à vos amis, votre famille et votre entourage ! Voici quelques faits importants concernant l'hépatite B : L’hépatite B n'est pas une maladie héréditaire : elle est causée par un virus.  Il existe un vaccin sûr qui vous protège pour la vie.  Le dépistage de l'hépatite B se fait par une simple analyse de sang.  Il existe des choix de traitement. L'hépatite B est une maladie présente partout dans le monde L’hépatite B peut infecter n'importe qui, peu importe son origine ou son âge. Cependant, les personnes qui viennent de régions où elle est la plus répandue (par exemple en Asie, dans certaines parties de l’Afrique et de l’Amérique du Sud, en Europe de l’Est et au Moyen-Orient) sont beaucoup plus susceptibles de contracter la maladie. L’hépatite B est courante également chez les Américains originaires (ou dont les parents sont originaires) de ces régions. Dans le monde, des centaines de millions de personnes sont atteintes de l'hépatite B. La plupart d'entre elles ne savent pas qu'elles sont infectées et ne présentent aucun symptôme. Mais il y a beaucoup de choses importantes à savoir au sujet de cette maladie. Le dépistage de l'hépatite B peut vous sauver la vie. En sachant si vous êtes porteur de la maladie, vous pourrez adapter votre mode de vie pour avoir un foie en bonne santé et vous pourrez consulter un médecin pour traiter le virus et prévenir les dommages au foie. La Hepatitis B Foundation est un organisme américain sans but lucratif dont la mission est de trouver une cure et d'améliorer la qualité de vie des personnes atteintes d'hépatite B dans le monde, par la recherche scientifique, l'information et la défense des intérêts des patients. Mentions légales : Les informations qui figurent sur ce site internet sont fournies à titre d'information uniquement. La Hepatitis B Foundation n'est pas un organisme médical. Veuillez contacter votre médecin ou un professionnel de la santé compétent pour une consultation personnelle.  Welcome to the French Chapter of the Hepatitis B Foundation Website Hepatitis B is known as a silent disease, and most people don’t even know they are infected. This website contains information about preventing, diagnosing and managing hepatitis B. We encourage you to share this information with your friends, family and others in your community. Here are some important things to remember about hepatitis B: Hepatitis B is not inherited - it is caused by a virus.  There is a safe vaccine which will protect you from hepatitis B for life.  There is a simple blood test to diagnose hepatitis B.  There are treatment options. Hepatitis B is a Global Disease Hepatitis B can infect any person of any age or ethnicity, but people from parts of the world where hepatitis B is common, such as Asia, parts of Africa and South America, Eastern Europe, and the Middle East, are at much higher risk for getting infected. Hepatitis B is also common among Americans who were born (or whose parents were born) in these regions. There are hundreds of millions of people worldwide who have hepatitis B. Most people don’t even know they are infected, and don’t have symptoms – but there are many important things you should know. Getting tested for hepatitis B can save your life. If you know you have hepatitis B, you can make lifestyle choices to keep your liver healthy and you can see a doctor to help manage the virus and prevent liver damage. The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and helping to improve the quality of life for all those affected by hepatitis B worldwide through research, education and patient advocacy. Disclaimer: The information that is provided on this website is for educational purposes only. The Hepatitis B Foundation is not a medical organization. Please talk to your doctor or a qualified health care provider for personal medical care and advice. 

    https://www.hepb.org/languages/french/
  • Fred Beans and Ding-Shinn Chen at its 2018 Crystal Ball Gala

    Evening raised $128,000 to advance research and programs for people with hepatitis B  DOYLESTOWN, PA (April 2018)- The Hepatitis B Foundation (HBF) hosted over 230 leaders from academia, industry, government and the community at its annual Crystal Ball Gala on April 6, 2018 at Pinecrest Country Club in Lansdale, PA.  The evening also included a ceremony to honor influential scientists in hepatitis B research and leaders in the local community. Over $128,000 was raised to support the organization's valuable research, outreach, public health, and patient advocacy programs. Guests at the gala enjoyed table casino games by Tumbling Dice, dinner and dancing, a silent auction and an awards ceremony honoring scientist Ding-Shinn Chen, MD; community leader Fred Beans; and featuring the screening of a video from the Foundation’s #justB patient storytelling campaign. During the evening’s ceremony, the Foundation’s most prestigious award, the Baruch S. Blumberg Prize, was presented to Prof. Ding-Shinn Chen, MD, FAASLD, distinguished chair professor, National Taiwan University College of Medicine. Dr. Chen was recognized for his pioneering work toward prevention and management of viral hepatitis and liver disease. His leadership efforts included identifying hepatitis B as the main cause of chronic liver disease and liver cancer in Taiwan, implementation of mass hepatitis B vaccination in Taiwan, and his role in the Hepatitis Control Committee of the Taiwanese government for over 30 years. Mr. Fred Beans, Founder and CEO of the Fred Beans Family of Dealerships, was honored with the 2018 Community Commitment Award for improving the community through his significant financial support and board service for over 30 years.  Among his numerous charitable endeavors, the Fred Beans Family of Dealerships have supported the HBF’s Summer High School Internship program for the past two years. The ceremony concluded with a screening of a video from the Foundation’s #justB campaign, featuring storytellers Kurt and Janet. The #justB campaign is a national storybank featuring real people living with hepatitis B who share their stories to put a human face on this serious disease. Following the video, Kurt and Janet provided an update on their story of adopting a baby born to a mother with hepatitis B. The Hepatitis B Foundation's 2018 Crystal Ball Gala was made possible with the generous support of Presenting Sponsor Univest Bank; Platinum Sponsors Arbutus Biopharma, Gilead Sciences, and Janssen Pharmaceuticals; Diamond Sponsors Arrowhead Pharmaceuticals, Dynavax, and Penn Community Bank; Emerald Sponsors Allure West Studios, de Art Folio Design, High Swartz LLC and Inovio Pharmaceuticals;  and Media Sponsor Bucks County Herald. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900.

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-honors-business-leader-fred-beans-and-scientist-ding-shinn-chen-at-its-2018-crystal-ball-gala/
  • Hepatitis B Foundation Appoints Global Expert Dr. Nat Brown to Its Board of Directors

    Dr. Nat Brown is a world-renowned hepatitis B drug development expert and Doylestown native  DOYLESTOWN, PA (February 2017) – The Hepatitis B Foundation, the nation’s leading nonprofit research and disease advocacy organization, is pleased to announce the appointment of Nathaniel Brown, M.D., a retired pharmaceutical executive living in San Francisco, to its Board of Directors. Dr. Brown is a Doylestown native who graduated from Central Bucks High School 50 years ago and has since become a renowned global leader in the field of antiviral drug discovery and development, with the past 20 years spent focused on hepatitis B. “The Hepatitis B Foundation is proud to have Dr. Nat Brown join the Board of Directors because he has made enormous contributions to improving the lives of those chronically infected with hepatitis B,” said Timothy M. Block, Ph.D., president and co-founder of the Hepatitis B Foundation. “Dr. Brown led the development, and eventual approval, of the first oral drug for hepatitis B, which not only spurred additional drug discovery, but also made liver transplantation an option for hepatitis B patients who had been previously excluded.” Dr. Brown is an infectious diseases physician with over 30 years of experience both in academic medicine at Cornell and UCLA, and as a senior executive in pharmaceutical drug development at GlaxoSmithKline, Idenix, Novira and other biotech companies. Prior to retiring in July 2016, he had leadership roles in multiple anti-viral/anti-infective drug development programs, resulting in U.S. and global product approvals for six new medicines for hepatitis B, hepatitis C, HIV/AIDS, and associated infections. As the global clinical leader for two HBV antivirals (lamivudine and telbivudine),Dr. Brown has extensive experience with globalized HBV drug development, including North and South America, Europe, India, Southeast Asia, and mainland China.  Dr. Brown has authored over 200 scientific publications and served in advisory roles to pharmaceutical and biotech companies, foundations, and government agencies (NIH and FDA). He studied Molecular Biophysics and Biochemistry at Yale University, received his Medical Degree from Georgetown University School of Medicine, completed clinical specialty training at The New York Hospital-Cornell Medical Center, and post-doctoral training in infectious diseases and virology at Yale University School of Medicine.  About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900. # # #

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-appoints-global-expert-dr-nat-brown-to-its-board-of-directors/
  • Hepatitis B: Is a Cure Possible?

    With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure. From the Spring 2016 B Informed Newsletter With the momentum growing around hepatitis B drug discovery research, how far are we from a cure? Closer than ever, according to Timothy Block, PhD, president and co-founder of the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute. He points out that hepatitis C, initially thought to be incurable, can now be cured with new combination treatments. “Hepatitis B is in a similar position,” Block believes. And the need for a cure has never been greater, with over 240 million people living with chronic hepatitis B infection worldwide, resulting in 1 million deaths per year from related liver failure and liver cancer. “Treatments are available,” explains Block, “but we have become a little too comfortable with the seven medications that are currently approved for use.” While these drugs are effective, the interferons have many side effects and the oral antivirals require lifelong use. Moreover, they work in only about half of the infected population, and reduce the rate of death due to liver disease by only about 40 to 70 percent. For those who benefit from treatment, the antiviral drugs prove that medications can be effective. However, there are millions who do not benefit and are still left vulnerable. “We should not accept that a significant number of people will still die from hepatitis B-related complications despite taking the current drugs,” Block declares. What would a cure look like? The current antiviral agents are similar and combinations do not offer any advantage. They have limited effectiveness against cccDNA, the seemingly indestructible “mini-chromosome” of the hepatitis B virus that continues to produce virus particles in infected liver cells, even in people being treated. A cure, therefore, would have to destroy or silence cccDNA and provide long-term protective immunity. Because one-drug treatments can lead to drug resistance, a cure would almost certainly involve combination therapy. With the recent advances in hepatitis B research, scientists are optimistic that another big leap in the search for a cure is possible if other complementary drugs can be found. The Baruch S. Blumberg Institute of the Hepatitis B Foundation is at the forefront of research efforts to discover such new drugs. Blumberg Institute at the forefront Blumberg scientists have played a key role in increasing understanding of the virus life cycle and are recognized leaders in drug discovery research that also includes designing and developing assays to screen for new drugs. “With our Drexel University colleagues, we are among the first, if not the only group, to identify a small molecule that inhibits hepatitis B virus cccDNA formation,” Block notes. This is significant because inhibition of cccDNA is considered essential in achieving a complete cure. Block is confident that a drug with this mechanism will eventually become available. In 2015, the Blumberg Institute licensed several of its discoveries to Arbutus Biopharma, the first company solely dedicated to hepatitis B drug discovery, and signed a three-year research agreement to work on novel approaches to developing a hepatitis B cure. “This unique partnership will allow us to move our discoveries more rapidly from the lab to the clinic,” Block explains. Adding to its drug arsenal, Blumberg researchers have used computer modeling to design and produce targeted drugs against hepatitis B and liver cancer. In another innovative approach, researchers are screening plant and fungal extracts from its Natural Products Collection, donated by Merck & Co. in 2011, and have already discovered two potential drugs that are active against hepatitis B. Getting close to the finish line “There has never been more optimism than right now that a cure is within reach,” says Block. “This is the goal of the Hepatitis B Foundation, so we are all very excited.” Blumberg researchers are building on recent discoveries that have heightened the momentum around finding a cure for hepatitis B and liver cancer: new screening methods to search for effective drugs; new ways to treat hepatitis B using different approaches to shut down the virus; a new blood biomarker that aids in the early detection of liver cancer; and a promising drug that selectively kills liver cancer cells in animal studies. “The years that we all have spent working towards a cure for hepatitis B have laid the groundwork for this final phase,” said Block. “We are committing everything we have, every resource at our disposal, to developing the therapies that will ultimately improve the lives of all people living with hepatitis B worldwide and ultimately relegate hepatitis B to the history books.” Baruch S. Blumberg Institute HBV Research Pipeline The Baruch S. Blumberg Institute (BSBI) of the Hepatitis B Foundation is leading the charge in developing innovative new therapies against hepatitis B. Among the products in the pipeline: cccDNA Inhibitors We are among the first, if not the only group, to identify the first small molecule inhibitor of HBV cccDNA, which has now been made highly active and is licensed to Arbutus Biopharma for further development. Capsid Inhibitors, “YES Kinase” Inhibitors We are using high-throughput screens and computer modeling to design and produce targeted drugs that include capsid inhibitors for HBV and “YES kinase” inhibitors for liver cancer. Immune System Activators We have developed a new HBV drug that works by activating an infected liver cell’s own immune system, which has been shown to be effective in animal studies. Natural Antiviral Agents We have screened thousands of plant and fungal extracts from our extensive Natural Products Collection and identified two new leads that show potential activity against HBV.

    https://www.hepb.org/news-and-events/free-newsletters/hepatitis-b-is-a-cure-possible/
  • Prevención y vacunación

    ¿Cómo me puedo contagiar de hepatitis B? La hepatitis B es una enfermedad infecciosa producida por un virus que se transmite a través de la sangre. A continuación se enumeran las vías de transmisión más frecuentes de la hepatitis B: Contacto directo con sangre o fluidos corporales infectados De una madre infectada a su bebé recién nacido durante el embarazo o el parto Sexo sin protección con una pareja infectada Agujas reutilizadas o compartidas (por ejemplo, compartir agujas para drogas ilegales o reutilizar agujas sin la esterilización adecuada para medicamentos, acupuntura, tatuajes o perforaciones corporales/orejas) Equipo médico o agujas no esterilizados que pueden usar los médicos, dentistas o barberos de carretera ¿La hepatitis B se transmite de manera casual? No, la hepatitis B no se transmite a través de contacto casual. Usted no puede infectarse de hepatitis B por el aire, los abrazos, al tocarse, estornudar, toser, a través de asientos sanitarios ni al tocar pomos o perillas de puertas. No puede infectarse de hepatitis B por comer o beber con alguien infectado ni por comer alimentos que preparó alguien que tiene hepatitis B. ¿Quién tiene más probabilidad de infectarse con hepatitis B?  Aunque todo el mundo tiene cierto riesgo de infectarse con hepatitis B, algunas personas tienen más probabilidad de infectarse. Su trabajo, estilo de vida o solo el hecho de haber nacido en una familia con hepatitis B pueden aumentar sus probabilidades de infectarse. A continuación se indican algunos de los grupos de "alto riesgo" más comunes, pero por favor recuerde que esta no es una lista completa: Personas casadas o que viven en contacto cercano en el hogar con alguien que tiene hepatitis B. Esto incluye adultos y niños. Personas que nacieron en países donde la hepatitis B es común, o cuyos padres nacieron en países donde la hepatitis B es común (Asia, zonas de África y América del Sur, el este de Europa y el Medio Oriente). Personas que viven o viajan a países donde la hepatitis B es común (Asia, zonas de África y América del Sur, el este de Europa y el Medio Oriente). Adultos y adolescentes sexualmente activos. Hombres que tienen relaciones sexuales con hombres. Bebés nacidos de madres infectadas. Trabajadores de salud y otros que están expuestos a la sangre en sus trabajos. Personal de emergencias. Receptores de transfusiones de sangre antes de 1992 o receptores más recientes de sangre que no se evaluó adecuadamente. Consumidores de drogas inyectables, en el pasado y en la actualidad. Personas que se hacen tatuajes o perforaciones corporales. Personas que utilizan los servicios de médicos, dentistas y barberos de carretera. Pacientes de diálisis renal. Residentes y personal de hogares grupales, instituciones o centros correccionales. ¿Cuáles son las recomendaciones en cuanto a la vacuna contra la hepatitis B? La OMS y los CDC de los EE. UU. recomiendan la vacuna contra la hepatitis B en todos los bebés y niños hasta los 18 años de edad. Los CDC también recomiendan que los adultos de grupos de alto riesgo se vacunen. La vacuna contra la hepatitis B es segura y eficaz, y se recomienda en todos los bebés al momento de nacer y en niños hasta los 18 años de edad. La vacuna contra la hepatitis B también se recomienda en adultos que tienen diabetes y los que tienen alto riesgo de infección debido al tipo de trabajo que tienen, estilo de vida, situación de vivienda o país de nacimiento. Debido a que todo el mundo tiene cierto riesgo de contraer la enfermedad, todos los adultos deberían considerar seriamente vacunarse contra la hepatitis B para una protección de por vida contra una enfermedad hepática crónica prevenible. ¿La vacuna contra la hepatitis B es segura? Sí; la vacuna contra la hepatitis B es muy segura y eficaz. De hecho, es la primera "vacuna anticancerosa" debido a que lo puede proteger de la hepatitis B, que es la causa del 80% de todos los cánceres hepáticos en el mundo. Con más de mil millones de dosis administradas en todo el mundo, los estudios médicos y científicos han demostrado que la vacuna contra la hepatitis B es una de las más seguras que se ha fabricado. ¿Puedo infectarme de hepatitis B por la vacuna? No; no se puede infectar de hepatitis B por la vacuna. La vacuna se fabrica de un producto de levadura sintética en un laboratorio. Los efectos secundarios más frecuentes son enrojecimiento y dolor en el brazo donde se administró la inyección. ¿Cuál es el esquema de vacunación de la hepatitis B? La vacuna contra la hepatitis B está disponible en el consultorio de su médico, en clínicas o en el departamento de salud local. Generalmente se requieren tres dosis para completar el esquema de vacunación contra la hepatitis B, aunque existe un esquema intensivo de dos dosis para adolescentes entre 11 y 15 años de edad, y la FDA aprobó en 2017 un nuevo esquema de vacunación de 2 dosis para su uso en adultos. Es importante recordar que los bebés nacidos de madres infectadas deben recibir la primera dosis de la vacuna contra la hepatitis B en la sala de parto o durante las primeras 12 horas de vida. 1.ª dosis: en cualquier momento, pero los recién nacidos deben recibir esta dosis en la sala de parto. 2.ª dosis: al menos un mes (o 28 días) después de la 1.ª dosis. 3.ª dosis: seis meses después de la 1.ª dosis (o al menos 2 meses después de la 2.ª dosis). Deben pasar al menos 16 semanas entre la 1.ª y la 3.ª dosis. Si tuvo un retraso en su esquema de vacunación, no necesita recomenzar el esquema, puede continuar desde donde lo dejó, incluso si han pasado años entre las dosis. Para tener la certeza de que está protegido contra la hepatitis B, pida que le hagan una prueba de sangre sencilla para verificar sus "títulos de anticuerpo para hepatitis B" (HBsAb), que confirmará si la vacunación fue exitosa. ¿Qué más puedo hacer para protegerme de la hepatitis B? Debido a que la hepatitis B se transmite a través de sangre infectada y fluidos corporales infectados, existen varias medidas sencillas que puede tomar para protegerse de una posible infección hasta que sus vacunas estén completas: Evite tocar directamente sangre o cualquier fluido corporal. Use condones con sus parejas sexuales. Evite el uso de drogas ilegales y el abuso de medicamentos con receta, incluyendo la inyección de los mismos. Evite compartir objetos cortantes como rasuradoras, cepillos de dientes, aretes y cortaúñas. Asegúrese de que se utilicen agujas y equipos estériles para medicina, odontología, acupuntura, tatuajes y perforaciones corporales y de las orejas. Use guantes y una solución fresca de lejía y agua para limpiar la sangre que se derrame. Lávese las manos profundamente con agua y jabón después de tocar o limpiar sangre. Lo más importante, ¡asegúrese de recibir la vacuna contra la hepatitis B!  Prevention and Vaccination  How can I get hepatitis B? Hepatitis B is an infectious disease caused by a virus that is spread through blood. Listed below are the most common ways hepatitis B is passed to others: Direct contact with infected blood or infected bodily fluids From an infected mother to her newborn baby during pregnancy or delivery Unprotected sex with an infected partner Shared or re-used needles (for example, sharing needles for illegal drugs or re-using needles that are not properly sterilized for medicine, acupuncture, tattoos, or ear/body piercing) Unsterilized medical equipment or needles that may be used by roadside doctors, dentists or barbers Is hepatitis B transmitted casually? No, hepatitis B is not spread through casual contact. You cannot get hepatitis B from the air, hugging, touching, sneezing, coughing, toilet seats or doorknobs. You cannot get hepatitis B from eating or drinking with someone who is infected or from eating food prepared by someone who has hepatitis B. Who is most likely to become infected with hepatitis B?  Although everyone is at some risk for getting hepatitis B, there are some people who are more likely to get infected. Your job, lifestyle, or just being born into a family with hepatitis B can increase your chances of being infected. Here are some of the most common "high risk" groups -- but please remember that this is not a complete list: People who are married to or live in close household contact with someone who has hepatitis B. This includes adults and children. People who were born countries where hepatitis B is common, or whose parents were born in countries where hepatitis B is common (Asia, parts of Africa and South America, Eastern Europe, and the Middle East). People who live in or travel to countries where hepatitis B is very common (Asia, parts of Africa and South America, Eastern Europe, and the Middle East). Sexually active adults and teenagers Men who have sex with men Infants born to infected mothers Healthcare workers and others who are exposed to blood in their jobs. Emergency personnel Recipients of blood transfusions before 1992, or more recent recipients of improperly screened blood Injection drug users, past and present People who get tattoos or body piercing People who use roadside doctors, dentists or barbers Patients who are on kidney dialysis Residents and staff of group homes, institutions, or correctional facilities. Recipients of blood transfusions before 1992, or more recent recipients of improperly screened blood Injection drug users, past and present People who get tattoos or body piercing People who use roadside doctors, dentists or barbers What are the recommendations for the hepatitis B vaccine? The hepatitis B vaccine is recommended for all infants and children up to age 18 years by the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC). The CDC also recommends that adults in high-risk groups be vaccinated. The hepatitis B vaccine is a safe and effective vaccine that is recommended for all infants at birth and for children up to 18 years. The hepatitis B vaccine is also recommended for adults living with diabetes and those at high risk for infection due to their jobs, lifestyle, living situations, or country of birth. Since everyone is at some risk, all adults should seriously consider getting the hepatitis B vaccine for a lifetime protection against a preventable chronic liver disease. Is the hepatitis B vaccine safe? Yes, the hepatitis B vaccine is very safe and effective. In fact, it is the first “anti-cancer vaccine” because it can protect you from hepatitis B, which is the cause of 80% of all liver cancer in the world. With more than one billion doses given throughout the world, medical and scientific studies have shown the hepatitis B vaccine to be one of the safest vaccines ever made. Can I get hepatitis B from the vaccine? No, you cannot get hepatitis B from the vaccine. The vaccine is made from a synthetic yeast product in a laboratory. The most common side effects are redness and soreness in the arm where the shot is given. What is the hepatitis B vaccine schedule? The hepatitis B vaccine is available at your doctor's office and local health department or clinic. Three doses are generally required to complete the hepatitis B vaccine series, although there is an accelerated two-dose series for adolescents age 11 through 15 years, and there is a new 2-dose vaccine that was approved by the U.S. Food and Drug Administration (FDA) for use in adults in 2017. It is important to remember that babies born to infected mothers must receive the first dose of hepatitis B vaccine in the delivery room or within the first 12 hours of life. 1st Shot - At any given time, but newborns should receive this dose in the delivery room 2nd Shot - At least one month (or 28 days) after the 1st shot 3rd Shot - Six months after the 1st shot (or at least 2 months after the 2nd shot) There must be at least 16 weeks between the 1st and 3rd shot. If your vaccine schedule has been delayed, you do not need to start the series over, you can continue from where you have left off – even if there have been years between doses. To be certain that you are protected against hepatitis B, ask for a simple blood test to check your “hepatitis B antibody titers” (HBsAb) which will confirm whether the vaccination was successful. What else can I do to protect myself from hepatitis B? Since hepatitis B is spread through infected blood and infected body fluids, there are several simple things that you can do to protect yourself from possible infection until your vaccination is complete: Avoid touching blood or any bodily fluids directly Use condoms with sexual partners Avoid illegal drugs and prescription drug misuse, including injection of such drugs Avoid sharing sharp objects such as razors, toothbrushes, earrings, and nail clippers Make sure that sterile needles and equipment are used for medicine, the dentist, acupuncture, tattoos, ear and body piercing Wear gloves and use a fresh solution of bleach and water to clean up blood spills Wash your hands thoroughly with soap and water after touching or cleaning up blood Most importantly, make sure you receive the hepatitis B vaccine!     

    https://www.hepb.org/languages/spanish/prevention/